Ricart et al., "A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors," Cancer Chemotherapy and Pharmacology, vol.
Priebe et al., "2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo," Cancer Research, vol.
Baradaran, "Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy," Journal of Breast Cancer, vol.
Chen et al., "Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1[alpha] and c-MYC," Leukemia & Lymphoma, vol.
Aft, "Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells," Journal of Cancer Research and Therapeutics, vol.
Role of T regulatory cells (CD[4.sup.+]CD[25.sup.+]FoxP[3.sup.+]) and Th1, Th2 and Th3 cytokines in the radiosensization of Ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose (2-DG).
Heterogeneity in 2-deoxy-D-glucose induced modifications in energetic and radiation responses of human tumor cell lines.
Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958; 2: 485-94.
Enhancement of radiation damage by 2-deoxy-D-glucose in organ cultures of brain tumours.
Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas.